Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy
Patients with household contacts meeting any of the following criteria are ineligible for study entry unless alternate living arrangements can be made, while under contact precautions.
Women who are pregnant or nursing an infant
Children \< 1 year old
Individuals who are severely immunocompromised
Contact precautions are from initial treatment with MG1-E6E7 to 7 days after the last dose of MG1-E6E7
Clareo Health | This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
